Interrogating novel compounds for improved anti-dengue therapies via inhibition of human hexokinase II (HKII)

• Main Authors: Ahmad Fuad, Fazia Adyani, Tanbin, Suriyea
• Format: Conference or Workshop Item
• Language: English
• Published: 2020
• Subjects: Q Science (General); QD Chemistry; RM Therapeutics. Pharmacology
• Online Access: http://irep.iium.edu.my/87224/1/Nanotech%20Symposium%202020%20Book%20Final%20-%20Fazia%20Nanotech%20Symposium%202020%20Book%20final.pdf; http://irep.iium.edu.my/87224/

Dengue is one of the most fatal infectious diseases in the world, which is caused by dengue virus (DENV). Regrettably until now, specific treatment for the disease has not been established. It has been reported that a human glycolytic enzyme, the human hexokinase II (HKII) has a great impact in supporting viral replication in the host cell, thus the enzyme has been proposed as an anti-DENV drug target. The main aim of this research is to identify novel anti-DENV agents for the treatment of dengue disease through in silico screening and HKII enzymatic inhibition studies.